Research Output per year
Research Output 1995 2019
- 1 - 50 out of 205 results
- Publication Year, Title (descending)
2019
1
Citation
(Scopus)
A Phase 2 Study of PCI-27483, a Factor VIIa Inhibitor in Combination with Gemcitabine for Advanced Pancreatic Cancer
Ramanathan, R. K., Thomas, G. W., Khorana, A. A., Shah, S., Zhou, C., Wong, S., Cole, G., James, D. & Gabrail, N. Y., Jan 1 2019, In : Oncology (Switzerland).Research output: Contribution to journal › Article
Open Access
gemcitabine
Factor VIIa
Pancreatic Neoplasms
Disease-Free Survival
Survival
Correction: A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer (British Journal of Cancer, (2019), 120, 2, (183-189), 10.1038/s41416-018-0343-z)
Gorbunova, V., Beck, J. T., Hofheinz, R. D., Garcia-Alfonso, P., Nechaeva, M., Gracian, A. C., Mangel, L., Fernandez, E. E., Deming, D. A., Ramanathan, R. K., Torres, A. H., Sullivan, D., Luo, Y. & Berlin, J. D., Jan 1 2019, In : British journal of cancer.Research output: Contribution to journal › Comment/debate
Open Access
Colorectal Neoplasms
Placebos
Neoplasms
veliparib
9
Citations
(Scopus)
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial
Shroff, R. T., Javle, M. M., Xiao, L., Kaseb, A. O., Varadhachary, G. R., Wolff, R. A., Raghav, K. P. S., Iwasaki, M., Masci, P., Ramanathan, R. K., Ahn, D., Bekaii-Saab, T. & Borad, M. J., Jan 1 2019, In : JAMA Oncology.Research output: Contribution to journal › Article
gemcitabine
Biliary Tract Neoplasms
Nanoparticles
Cisplatin
Clinical Trials
15
Citations
(Scopus)
Hepatocytes direct the formation of a pro-metastatic niche in the liver
Lee, J. W., Stone, M. L., Porrett, P. M., Thomas, S. K., Komar, C. A., Li, J. H., Delman, D., Graham, K., Gladney, W. L., Hua, X., Black, T. A., Chien, A. L., Majmundar, K. S., Thompson, J. C., Yee, S. S., O’Hara, M. H., Aggarwal, C., Xin, D., Shaked, A., Gao, M. & 9 others, , Mar 14 2019, In : Nature. 567, 7747, p. 249-252 4 p.Research output: Contribution to journal › Letter
Hepatocytes
Liver
STAT3 Transcription Factor
Neoplasm Metastasis
Circulating Neoplastic Cells
8
Citations
(Scopus)
Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313
Ramanathan, R. K., McDonough, S. L., Philip, P. A., Hingorani, S. R., Lacy, J., Kortmansky, J. S., Thumar, J., Chiorean, E. G., Shields, A. F., Behl, D., Mehan, P. T., Gaur, R., Seery, T., Guthrie, K. A. & Hochster, H. S., May 1 2019, In : Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 37, 13, p. 1062-1069 8 p.Research output: Contribution to journal › Article
Hyaluronoglucosaminidase
Adenocarcinoma
Hyaluronic Acid
Survival
irinotecan
Response Rate Following Albumin-Bound Paclitaxel Plus Gemcitabine Plus Cisplatin Treatment among Patients with Advanced Pancreatic Cancer: A Phase 1b/2 Pilot Clinical Trial
Jameson, G. S., Borazanci, E., Babiker, H. M., Poplin, E., Niewiarowska, A. A., Gordon, M. S., Barrett, M. T., Rosenthal, A., Stoll-D'astice, A., Crowley, J., Shemanski, L., Korn, R. L., Ansaldo, K., Lebron, L., Ramanathan, R. K. & Von Hoff, D. D., Jan 1 2019, (Accepted/In press) In : JAMA Oncology.Research output: Contribution to journal › Article
gemcitabine
Pancreatic Neoplasms
Cisplatin
Clinical Trials
Therapeutics
2018
4
Citations
(Scopus)
A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours
Berlin, J., Ramanathan, R. K., Strickler, J. H., Subramaniam, D. S., Marshall, J., Kang, Y. K., Hetman, R., Dudley, M. W., Zeng, J., Nickner, C., Xiong, H., Komarnitsky, P., Shepherd, S. P., Hurwitz, H. & Lenz, H. J., Mar 12 2018, (Accepted/In press) In : British Journal of Cancer. p. 1-9 9 p.Research output: Contribution to journal › Article
irinotecan
Neoplasms
Fluorouracil
Maximum Tolerated Dose
Leucovorin
1
Citation
(Scopus)
A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer
Gorbunova, V., Beck, J. T., Hofheinz, R. D., Garcia-Alfonso, P., Nechaeva, M., Cubillo Gracian, A., Mangel, L., Elez Fernandez, E., Deming, D. A., Ramanathan, R. K., Torres, A. H., Sullivan, D., Luo, Y. & Berlin, J. D., Jan 1 2018, (Accepted/In press) In : British Journal of Cancer.Research output: Contribution to journal › Article
Colorectal Neoplasms
Placebos
Neutropenia
Disease-Free Survival
veliparib
20
Citations
(Scopus)
Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors
Moschos, S. J., Sullivan, R. J., Hwu, W. J., Ramanathan, R. K., Adjei, A. A., Fong, P. C., Shapira-Frommer, R., Tawbi, H. A., Rubino, J., Rush, T. S., Zhang, D., Miselis, N. R., Samatar, A. A., Chun, P., Rubin, E. H., Schiller, J., Long, B. J., Dayananth, P., Carr, D., Kirschmeier, P. & 8 others, , Feb 22 2018, In : JCI insight. 3, 4Research output: Contribution to journal › Article
Open Access
Neoplasms
Melanoma
Clinical Trials, Phase I
Exanthema
Heterografts
3
Citations
(Scopus)
Emerging therapies and future directions in targeting the tumor stroma and immune system in the treatment of pancreatic adenocarcinoma
Ahn, D., Ramanathan, R. K. & Bekaii-Saab, T., Jun 11 2018, In : Cancers. 10, 6, 193.Research output: Contribution to journal › Review article
Immune System
Adenocarcinoma
Neoplasms
Therapeutics
Aptitude
3
Citations
(Scopus)
First-in-human phase I, dose-escalation and -expansion study of telisotuzumab vedotin, an antibody–drug conjugate targeting c-Met, in patients with advanced solid tumors
Strickler, J. H., Weekes, C. D., Nemunaitis, J., Ramanathan, R. K., Heist, R. S., Morgensztern, D., Angevin, E., Bauer, T. M., Yue, H., Motwani, M., Parikh, A., Reilly, E. B., Afar, D., Naumovski, L. & Kelly, K., Nov 20 2018, In : Journal of Clinical Oncology. 36, 33, p. 3298-3306 9 p.Research output: Contribution to journal › Article
Non-Small Cell Lung Carcinoma
Neoplasms
Maximum Tolerated Dose
Safety
Fatigue
22
Citations
(Scopus)
Metastatic pancreatic cancer: ASCO clinical practice guideline update
Sohal, D. P. S., Kennedy, E. B., Khorana, A., Copur, M. S., Crane, C. H., Garrido-Laguna, I., Krishnamurthi, S., Moravek, C., O'Reilly, E. M., Philip, P. A., Ramanathan, R. K., Ruggiero, J. T., Shah, M. A., Urba, S., Uronis, H. E., Lau, M. W. & Laheru, D., Aug 20 2018, In : Journal of Clinical Oncology. 36, 24, p. 2545-2556 12 p.Research output: Contribution to journal › Review article
irinotecan
Pancreatic Neoplasms
Practice Guidelines
gemcitabine
Fluorouracil
Novel immunotherapy strategies for hepatobiliary cancers
Deleon, T. T., Zhou, Y., Nagalo, B., Yokoda, R. T., Ahn, D., Ramanathan, R. K., Salomao, M. A., Aqel, B. A., Mahipal, A., Bekaii-Saab, T. & Borad, M. J., Sep 1 2018, In : Immunotherapy. 10, 12, p. 1077-1091 15 p.Research output: Contribution to journal › Review article
Immunotherapy
Neoplasms
Oncolytic Virotherapy
Therapeutics
T-Cell Antigen Receptor
9
Citations
(Scopus)
Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma
Deleon, T. T., Ahn, D., Bogenberger, J. M., Anastasiadis, P. Z., Arora, M., Ramanathan, R. K., Aqel, B. A., Vasmatzis, G., Truty, M., Oklu, R., Bekaii-Saab, T. & Borad, M. J., Mar 1 2018, In : Future Oncology. 14, 6, p. 553-566 14 p.Research output: Contribution to journal › Review article
Biliary Tract Neoplasms
Hepatocellular Carcinoma
Neoplasms
Biomarkers
Therapeutics
17
Citations
(Scopus)
Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours
Infante, J. R., Korn, R. L., Rosen, L. S., Lorusso, P., Dychter, S. S., Zhu, J., Maneval, D. C., Jiang, P., Shepard, H. M., Frost, G., Von Hoff, D. D., Borad, M. J. & Ramanathan, R. K., Jan 1 2018, In : British Journal of Cancer. 118, 2, p. 153-161 9 p.Research output: Contribution to journal › Article
Hyaluronoglucosaminidase
Neoplasms
Hyaluronic Acid
Maximum Tolerated Dose
Myalgia
74
Citations
(Scopus)
Phase II study of BGJ398 in patients with FGFR-Altered advanced cholangiocarcinoma
Javle, M., Lowery, M., Shroff, R. T., Weiss, K. H., Springfeld, C., Borad, M. J., Ramanathan, R. K., Goyal, L., Sadeghi, S., Macarulla, T., El-Khoueiry, A., Kelley, R. K., Borbath, I., Choo, S. P., Oh, D. Y., Philip, P. A., Chen, L. T., Reungwetwattana, T., Van Cutsem, E., Yeh, K. H. & 9 others, , Jan 20 2018, In : Journal of Clinical Oncology. 36, 3, p. 276-282 7 p.Research output: Contribution to journal › Article
Receptor, Fibroblast Growth Factor, Type 2
Cholangiocarcinoma
Hyperphosphatemia
Stomatitis
gemcitabine
4
Citations
(Scopus)
Phase I study of enavatuzumab, a first-in-class humanized monoclonal antibody targeting the TWEAK receptor, in patients with advanced solid tumors
Lam, E. T., Eckhardt, S. G., Messersmith, W., Jimeno, A., O'Bryant, C. L., Ramanathan, R. K., Weiss, G. J., Chadha, M., Oey, A., Ding, H. T., Culp, P. A., Keller, S. F., Zhao, V. Y., Tsao, L. C., Singhal, A., Holen, K. D. & Von Hoff, D., Jan 1 2018, In : Molecular Cancer Therapeutics. 17, 1, p. 215-221 7 p.Research output: Contribution to journal › Article
Antibodies, Monoclonal, Humanized
Pharmacokinetics
Neoplasms
Liver
Enzymes
2017
3
Citations
(Scopus)
18F-FDG PET/CT response in a phase 1/2 trial of nab-paclitaxel plus gemcitabine for advanced pancreatic cancer
Korn, R. L., Von Hoff, D. D., Borad, M. J., Renschler, M. F., McGovern, D., Curtis Bay, R. & Ramanathan, R. K., Aug 3 2017, In : Cancer Imaging. 17, 1, 23.Research output: Contribution to journal › Article
gemcitabine
Fluorodeoxyglucose F18
Pancreatic Neoplasms
Positron-Emission Tomography
Survival
A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patients
Ramanathan, R. K., Weiss, G. J., Posner, R. G., Rajeshkumar, N. V., Jameson, G., Aziz, M., Hoering, A., Bolejack, V., Maitra, A., Fulk, M., Stites, E. C., Hlavacek, W. S., Gatalica, Z., Xiu, J., Hidalgo, M., Von Hoff, D. D. & Barrett, M., Dec 1 2017, In : Journal of Gastrointestinal Oncology. 8, 6, p. 925-935 11 p.Research output: Contribution to journal › Article
Pancreatic Neoplasms
Immunohistochemistry
Neoplasms
Biopsy
irinotecan
10
Citations
(Scopus)
Clinical study of genomic drivers in pancreatic ductal adenocarcinoma
Barrett, M., Deiotte, R., Lenkiewicz, E., Malasi, S., Holley, T., Evers, L., Posner, R. G., Jones, T., Han, H., Sausen, M., Velculescu, V. E., Drebin, J., O'Dwyer, P., Jameson, G., Ramanathan, R. K. & Von Hoff, D. D., Aug 8 2017, In : British Journal of Cancer. 117, 4, p. 572-582 11 p.Research output: Contribution to journal › Article
Adenocarcinoma
Genome
Neoplasms
DNA Repair-Deficiency Disorders
Clinical Trials
41
Citations
(Scopus)
Correlation between ferumoxytol uptake in tumor lesions by MRI and response to nanoliposomal irinotecan in patients with advanced solid tumors: A pilot study
Ramanathan, R. K., Korn, R. L., Raghunand, N., Sachdev, J. C., Newbold, R. G., Jameson, G., Fetterly, G. J., Prey, J., Klinz, S. G., Kim, J., Cain, J., Hendriks, B. S., Drummond, D. C., Bayever, E. & Fitzgerald, J. B., Jul 15 2017, In : Clinical Cancer Research. 23, 14, p. 3638-3648 11 p.Research output: Contribution to journal › Article
irinotecan
Ferrosoferric Oxide
Neoplasms
Development of new pharmaceutical therapies for pancreatic adenocarcinoma
Ramanathan, R. K., Nov 1 2017, In : Clinical Advances in Hematology and Oncology. 15, 11, p. 7-10 4 p.Research output: Contribution to journal › Article
Adenocarcinoma
Pharmaceutical Preparations
Therapeutics
24
Citations
(Scopus)
Immunotherapy in pancreatic cancer treatment: A new frontier
Thind, K., Padrnos, L. J., Ramanathan, R. K. & Borad, M. J., Jan 1 2017, In : Therapeutic Advances in Gastroenterology. 10, 1, p. 168-194 27 p.Research output: Contribution to journal › Review article
Pancreatic Neoplasms
Immunotherapy
Tumor Microenvironment
Therapeutics
Immune Tolerance
116
Citations
(Scopus)
Phase I, dose-escalation, two-part trial of the PARP inhibitor talazoparib in patients with advanced germline BRCA1/2 mutations and selected sporadic cancers
de Bono, J., Ramanathan, R. K., Mina, L., Chugh, R., Glaspy, J., Rafii, S., Kaye, S., Sachdev, J., Heymach, J., Smith, D. C., Henshaw, J. W., Herriott, A., Patterson, M., Curtin, N. J., Byers, L. A. & Wainberg, Z. A., 2017, In : Cancer Discovery. 7, 6, p. 620-629 10 p.Research output: Contribution to journal › Article
Mutation
Neoplasms
Small Cell Lung Carcinoma
Antineoplastic Agents
Ovarian Neoplasms
5
Citations
(Scopus)
Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors
Weiss, G. J., Jameson, G., von Hoff, D. D., Valsasina, B., Davite, C., Di Giulio, C., Fiorentini, F., Alzani, R., Carpinelli, P., Di Sanzo, A., Galvani, A., Isacchi, A. & Ramanathan, R. K., Jul 20 2017, (Accepted/In press) In : Investigational New Drugs. p. 1-11 11 p.Research output: Contribution to journal › Article
Maximum Tolerated Dose
Neoplasms
Oral Administration
Safety
Therapeutics
52
Citations
(Scopus)
Phase I dose-escalation study of taselisib, an oral PI3K inhibitor, in patients with advanced solid tumors
Juric, D., Krop, I., Ramanathan, R. K., Wilson, T. R., Ware, J. A., Sanabria Bohorquez, S. M., Savage, H. M., Sampath, D., Salphati, L., Lin, R. S., Jin, H., Parmar, H., Hsu, J. Y., Von Hoff, D. D. & Baselga, J., Jul 1 2017, In : Cancer Discovery. 7, 7, p. 704-715 12 p.Research output: Contribution to journal › Article
Phosphatidylinositol 3-Kinases
Neoplasms
Growth Inhibitors
Stomatitis
Mutation
15
Citations
(Scopus)
Potential actionable targets in appendiceal cancer detected by immunohistochemistry, fluorescent in situ hybridization, and mutational analysis
Borazanci, E., Millis, S. Z., Kimbrough, J., Doll, N., von Hoff, D. & Ramanathan, R. K., 2017, In : Journal of Gastrointestinal Oncology. 8, 1, p. 164-172 9 p.Research output: Contribution to journal › Article
Appendiceal Neoplasms
Fluorescence In Situ Hybridization
Immunohistochemistry
irinotecan
Goblet Cells
Recent advances in the treatment of pancreatic adenocarcinoma: Further observations
Ramanathan, R. K. & Bekaii-Saab, T., Nov 1 2017, In : Clinical Advances in Hematology and Oncology. 15, 11, 1 p.Research output: Contribution to journal › Comment/debate
Adenocarcinoma
Recent advances in the treatment of pancreatic adenocarcinoma
Braiteh, F., Ramanathan, R. K. & Bekaii-Saab, T., Nov 1 2017, In : Clinical Advances in Hematology and Oncology. 15, 11, p. 1-2 2 p.Research output: Contribution to journal › Article
gemcitabine
Pancreatic Neoplasms
Adenocarcinoma
irinotecan
oxaliplatin
9
Citations
(Scopus)
Second-line treatment in patients with pancreatic ductal adenocarcinoma: A meta-analysis
Sonbol, M. B., Firwana, B., Wang, Z., Almader-Douglas, D., Borad, M. J., Makhoul, I., Ramanathan, R. K., Ahn, D. & Bekaii-Saab, T., Dec 1 2017, In : Cancer. 123, 23, p. 4680-4686 7 p.Research output: Contribution to journal › Article
oxaliplatin
irinotecan
Meta-Analysis
Adenocarcinoma
Disease-Free Survival
1
Citation
(Scopus)
Targeting the stroma in pancreatic cancer
Ahn, D. & Ramanathan, R. K., Dec 1 2017, In : Chinese Clinical Oncology. 6, 6, 65.Research output: Contribution to journal › Review article
Pancreatic Neoplasms
Tumor Microenvironment
Therapeutic Uses
Immunosuppression
Neoplasms
10
Citations
(Scopus)
Tumor reduction in primary andmetastatic pancreatic cancer lesions with nab-paclitaxel and gemcitabine: An exploratory analysis from a phase 3 study
Kunzmann, V., Ramanathan, R. K., Goldstein, D., Liu, H., Ferrara, S., Lu, B., Renschler, M. F. & Von Hoff, D. D., 2017, In : Pancreas. 46, 2, p. 203-208 6 p.Research output: Contribution to journal › Article
gemcitabine
Pancreatic Neoplasms
Tumor Burden
Neoplasms
Adenocarcinoma
Virotherapies in pancreatic cancer
Ahn, D. & Ramanathan, R. K., Sep 27 2017, Current and Emerging Therapies in Pancreatic Cancer. Springer International Publishing, p. 309-322 14 p.Research output: Chapter in Book/Report/Conference proceeding › Chapter
Pancreatic Neoplasms
2016
1
Citation
(Scopus)
A Case Report of Ischemic Stroke in a Patient with Metastatic Gastric Cancer Secondary to Treatment with the Vascular Endothelial Growth Factor Receptor-2 Inhibitor Ramucirumab
Christiansen, M. E., Ingall, T., Lew, E. C., Ramanathan, R. K. & Paripati, H., 2016, In : Case Reports in Oncology. 9, 2, p. 317-320 4 p.Research output: Contribution to journal › Article
Vascular Endothelial Growth Factor Receptor-2
Stomach Neoplasms
Stroke
Thromboembolism
Brain Ischemia
37
Citations
(Scopus)
CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer
Chiorean, E. G., Von Hoff, D. D., Reni, M., Arena, F. P., Infante, J. R., Bathini, V. G., Wood, T. E., Mainwaring, P. N., Muldoon, R. T., Clingan, P. R., Kunzmann, V., Ramanathan, R. K., Tabernero, J., Goldstein, D., McGovern, D., Lu, B. & Ko, A., Apr 1 2016, In : Annals of Oncology. 27, 4, p. 654-660 7 p., mdw006.Research output: Contribution to journal › Article
gemcitabine
Pancreatic Neoplasms
Survival
130-nm albumin-bound paclitaxel
29
Citations
(Scopus)
Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: A cohort study
Kasi, P. M., Kotani, D., Cecchini, M., Shitara, K., Ohtsu, A., Ramanathan, R. K., Hochster, H. S., Grothey, A. F. & Yoshino, T., Jul 13 2016, In : BMC Cancer. 16, 1, 467.Research output: Contribution to journal › Article
Neutropenia
Colorectal Neoplasms
Cohort Studies
Drug Therapy
Survival
10
Citations
(Scopus)
Clinical Implementation of Integrated Genomic Profiling in Patients with Advanced Cancers
Borad, M. J., Egan, J. B., Condjella, R. M., Liang, W. S., Fonseca, R., Ritacca, N. R., McCullough, A. E., Barrett, M., Hunt, K. S., Champion, M. D., Patel, M. D., Young, S. W., Silva, A. C., Ho, T. H., Halfdanarson, T. R., Mc Williams, R. R., Lazaridis, K. N., Ramanathan, R. K., Baker, A., Aldrich, J. & 17 others, , 2016, In : Scientific Reports. 6, 1, 25.Research output: Contribution to journal › Article
Neoplasms
Therapeutics
DNA Fingerprinting
Patient Preference
Pharmaceutical Preparations
17
Citations
(Scopus)
Development of peripheral neuropathy and its association with survival during treatment with nab-paclitaxel plus gemcitabine for patients with metastatic adenocarcinoma of the pancreas: A subset analysis from a randomised phase III trial (MPACT)
Goldstein, D., Von Hoff, D. D., Moore, M., Greeno, E., Tortora, G., Ramanathan, R. K., Macarulla, T., Liu, H., Pilot, R., Ferrara, S. & Lu, B., Jan 1 2016, In : European Journal of Cancer. 52, p. 85-91 7 p.Research output: Contribution to journal › Article
gemcitabine
Peripheral Nervous System Diseases
Pancreas
Adenocarcinoma
Survival
19
Citations
(Scopus)
Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: Phase III MPACT trial
Scheithauer, W., Ramanathan, R. K., Moore, M., Macarulla, T., Goldstein, D., Hammel, P., Kunzmann, V., Liu, H., McGovern, D., Romano, A. & Von Hoff, D. D., Jun 1 2016, In : Journal of Gastrointestinal Oncology. 7, 3, p. 469-478 10 p.Research output: Contribution to journal › Article
gemcitabine
Pancreatic Neoplasms
Neutropenia
Thrombocytopenia
Fatigue
57
Citations
(Scopus)
First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas
Patnaik, A., Appleman, L. J., Tolcher, A. W., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Weiss, G. J., Sachdev, J. C., Chadha, M., Fulk, M., Ejadi, S., Mountz, J. M., Lotze, M. T., Toledo, F. G. S., Chu, E., Jeffers, M., Peña, C., Xia, C., Reif, S., Genvresse, I. & 1 others, , Oct 1 2016, In : Annals of oncology : official journal of the European Society for Medical Oncology. 27, 10, p. 1928-1940 13 p.Research output: Contribution to journal › Article
Class I Phosphatidylinositol 3-Kinases
Non-Hodgkin's Lymphoma
Maximum Tolerated Dose
Neoplasms
Follicular Lymphoma
3
Citations
(Scopus)
Hepatoid Carcinoma of the Pancreas: Case Report, Next-Generation Tumor Profiling, and Literature Review
Chang, J. M., Katariya, N. N., Lam-Himlin, D. M., Haakinson, D. J., Ramanathan, R. K., Halfdanarson, T. R., Borad, M. J., Pannala, R., Faigel, D. O., Moss, A. A. & Mathur, A., Oct 18 2016, (Accepted/In press) In : Case Reports in Gastroenterology. p. 605-612 8 p.Research output: Contribution to journal › Article
Pancreas
Carcinoma
Acinar Cell Carcinoma
Neoplasms
Neuroendocrine Cells
119
Citations
(Scopus)
Metastatic pancreatic cancer: American Society of Clinical Oncology clinical practice guideline
Sohal, D. P. S., Mangu, P. B., Khorana, A. A., Shah, M. A., Philip, P. A., O'Reilly, E. M., Uronis, H. E., Ramanathan, R. K., Crane, C. H., Engebretson, A., Ruggiero, J. T., Copur, M. S., Lau, M., Urba, S. & Laheru, D., Aug 10 2016, In : Journal of Clinical Oncology. 34, 23, p. 2784-2796 13 p.Research output: Contribution to journal › Review article
gemcitabine
irinotecan
Pancreatic Neoplasms
Practice Guidelines
Comorbidity
78
Citations
(Scopus)
Phase I study of PSMA-targeted docetaxel-containing nanoparticle BIND-014 in patients with advanced solid tumors
Von Hoff, D. D., Mita, M. M., Ramanathan, R. K., Weiss, G. J., Mita, A. C., Lorusso, P. M., Burris, H. A., Hart, L. L., Low, S. C., Parsons, D. M., Zale, S. E., Summa, J. M., Youssoufian, H. & Sachdev, J. C., Jul 1 2016, In : Clinical Cancer Research. 22, 13, p. 3157-3163 7 p.Research output: Contribution to journal › Article
docetaxel
Nanoparticles
Appointments and Schedules
Pharmacokinetics
Neoplasms
Positron emission tomography (PET) as a predictive measure in patients with metastatic pancreatic cancer and normal CA19-9 levels at baseline
Ramanathan, R. K., Korn, R. L., Chiorean, E. G., Liu, H. & Von Hoff, D. D., Aug 1 2016, In : Annals of Oncology. 27, 8, p. 1647-1648 2 p.Research output: Contribution to journal › Letter
Pancreatic Neoplasms
Positron-Emission Tomography
20
Citations
(Scopus)
Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas
Ramanathan, R. K., Goldstein, D., Korn, R. L., Arena, F., Moore, M., Siena, S., Teixeira, L., Tabernero, J., Van Laethem, J. L., Liu, H., McGovern, D., Lu, B. & Von Hoff, D. D., Apr 1 2016, In : Annals of Oncology. 27, 4, p. 648-653 6 p., mdw020.Research output: Contribution to journal › Article
gemcitabine
Positron-Emission Tomography
Pancreas
Adenocarcinoma
Electrons
24
Citations
(Scopus)
Safety, pharmacokinetics, and pharmacodynamics of a humanized anti-semaphorin 4D antibody, in a first-in-human study of patients with advanced solid tumors
Patnaik, A., Weiss, G. J., Leonard, J. E., Rasco, D., Sachdev, J. C., Fisher, T. L., Winter, L. A., Reilly, C., Parker, R. B., Mutz, D., Blaydorn, L., Tolcher, A. W., Zauderer, M. & Ramanathan, R. K., Feb 15 2016, In : Clinical Cancer Research. 22, 4, p. 827-836 10 p.Research output: Contribution to journal › Article
Pharmacokinetics
Safety
Antibodies
Neoplasms
Cell Membrane
26
Citations
(Scopus)
Safety and activity of IT-139, a ruthenium-based compound, in patients with advanced solid tumours: A first-in-human, open-label, dose-escalation phase i study with expansion cohort
Burris, H. A., Bakewell, S., Bendell, J. C., Infante, J., Jones, S. F., Spigel, D. R., Weiss, G. J., Ramanathan, R. K., Ogden, A. & Von Hoff, D., Dec 1 2016, In : ESMO Open. 1, 6, e000154.Research output: Contribution to journal › Article
Ruthenium Compounds
Safety
Maximum Tolerated Dose
Neoplasms
Pharmacokinetics
2015
5
Citations
(Scopus)
90Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies
Picozzi, V. J., Ramanathan, R. K., Lowery, M. A., Ocean, A. J., Mitchel, E. P., O'neil, B. H., Guarino, M. J., Conkling, P. R., Cohen, S. J., Bahary, N., Frank, R. C., Dragovich, T., Bridges, B. B., Braiteh, F. S., Starodub, A. N., Lee, F. C., Gribbin, T. E., Richards, D. A., Lee, M., Korn, R. L. & 11 others, , Jun 7 2015, In : European Journal of Cancer. 51, 14, p. 1857-1864 8 p., 9522.Research output: Contribution to journal › Article
gemcitabine
Pancreatic Neoplasms
Adenocarcinoma
Therapeutics
Radioimmunotherapy
3
Citations
(Scopus)
A randomized, crossover phase 1 study to assess the effects of formulation (capsule vs tablet) and meal consumption on the bioavailability of dovitinib (TKI258)
Infante, J. R., Ramanathan, R. K., George, D., Tan, E., Quinlan, M., Liu, A., Scott, J. W. & Sharma, S., 2015, In : Cancer Chemotherapy and Pharmacology. 75, 4, p. 729-737 9 p.Research output: Contribution to journal › Article
Biological Availability
Tablets
Capsules
Meals
Fats
58
Citations
(Scopus)
Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer
Barrett, M., Anderson, K. S., Lenkiewicz, E., Andreozzi, M., Cunliffe, H. E., Klassen, C. L., Dueck, A., McCullough, A. E., Reddy, S. K., Ramanathan, R. K., Northfelt, D. W. & Pockaj, B. A., 2015, In : Oncotarget. 6, 28, p. 26483-26493 11 p.Research output: Contribution to journal › Article
Triple Negative Breast Neoplasms
Comparative Genomic Hybridization
Glioblastoma
Oligonucleotide Array Sequence Analysis
Disease-Free Survival